(Q42787231)

7 November 2017

title

Lenalidomide: an update on evidence from clinical trials (English)

1 reference

7 November 2017

author

Athanasios Dimopoulos

series ordinal

1

1 reference

7 November 2017

Evangelos Terpos

2

1 reference

7 November 2017

publication date

1 November 2010

1 reference

7 November 2017

1 reference

7 November 2017

volume

24 Suppl 1

1 reference

7 November 2017

page(s)

S21-6

1 reference

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2810%2970005-9

7 January 2021

10.1016/S0268-960X(10)70005-9

Identifiers

DOI

1 reference

7 November 2017

1 reference